Skip to content
DraconiticResearch
Search Sources API
203,948 studies31 sourcesUpdated 18 min ago
Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research

Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study

Read full textPDFCite

Related

  1. Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study
    Juemin Yu, Jialiang Wen, Tao Chen +8
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  2. Association between adjuvant EGFR-TKI therapy and survival outcomes in completely resected stage I invasive lung adenocarcinoma (≤3 cm) with sensitizing EGFR mutations and pathological high-risk features.
    Jie Cao, Zhaokang Huang, Fang Qiu +9
    Translational lung cancer researchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  3. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
    S. Dalle, P. Saiag, C. Lebbé +13
    European journal of cancer skin cancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyEpidemiology & public healthHAL
  4. Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
    Jamie E. Chaft, Zhuoxin Sun, Charles M. Rudin +26
    JAMAPeer-reviewedLicence not stated9 citedOncologyOpenAlex
  5. Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases
    Kozo Kataoka, Kazuma Ito, Yoshiaki Nakamura +35
    JAMA OncologyPeer-reviewedLicence not stated11 citedOncologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{anon2026adjuvant,
  title = {{Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study}},
  journal = {Translational Lung Cancer Research},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13657874},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study
PY  - 2026
DA  - 2026/08/31
JO  - Translational Lung Cancer Research
UR  - https://europepmc.org/article/PMC/PMC13657874
SN  - 2218-6751
ER  -